Safdar A*, Rodriguez G, Champlin RE. Feasibility of recombinant interferon-gamma therapy in hematopoietic stem cell transplant recipients receiving donor granulocyte transfusions for refractory mycosis. Abstract # 702. The 42nd Annual Meeting of the Infectious Diseases Society of America. September 30–October 3rd, 2004, Boston. February 2, 2018/in Research Presentations/by Amar Safdar
Adachi JA, Tarrand JJ, Rolston KV, Safdar A.Spectrum of non-Clostridium difficilebacterial enteric pathogens in hospitalized cancer patients with diarrhea during 1997–2004. Abstract # 681. The 42nd Annual Meeting of the Infectious Diseases Society of America. September 30–October 3rd, 2004, Boston. February 2, 2018/in Research Presentations/by Amar Safdar
Kumashi P, Girgawy EA, Tarrand JJ, Rolston KV, Safdar A.*Streptococcus pneumoniaebacteremia in 128 cancerpatients during 1998 to 2002. Abstract # 678. The 42nd Annual Meeting of the Infectious Diseases Society of America. September 30–October 3rd, 2004, Boston. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Rodriguez G, Champlin RE. Therapeutic efficacy of adjuvant recombinant interferon gamma-1b in hematopoietic stem cell transplant recipients with invasive mycosis. Abstract # 673. World Conference on Magic Bullets. International Society of Chemotherapy. September 9–11, 2004, Nürnberg, Germany ORAL PRESENTATION February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Rodriguez G, Omhagari N, Champlin RE. Impact of interferon-gammaadjuvant therapy on graft-versus-host disease in allogeneic hematopoietic stem cell transplant recipients. Abstract # 37. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. Granada, Spain June 27–30, 2004. Int J Infect Dis 2004; 8(Suppl1): S20. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Rodriguez G, Omhagari N, Champlin RE. Safety of recombinant interferon-gamma adjuvant therapy for invasive fungal infections in the recipients of hematopoietic stem cell transplantation. Abstract # 36. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. Granada, Spain June 27–30, 2004. Int JInfectDis2004; 8(Suppl1): S20. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, O’Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Abstract # 87. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. Granada, Spain June 27–30, 2004. International Journal of Infectious Diseases 2004; 8(Suppl1): S50. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Gonzalez O, Girgawy E. Changing spectrum of post-viral pneumonia in hospitalized patients with cancer. Abstract # 64. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. Granada, Spain June 27–30, 2004. International Journal of Infectious Diseases 2004; 8(Suppl1): S36. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Girgawy EA. Susceptibility profile of 288 Streptococcus pneumoniae in patients with cancer (1998–2002). Abstract # 63. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society (ICHS). Granada, Spain June 27–30, 2004. International Journal of Infectious Diseases 2004; 8(Suppl1): S35. February 2, 2018/in Research Presentations/by Amar Safdar
Safdar A*, Rolston KIV. Vancomycin-tolerant non-enterococcal Gram-positive bacteremia – an emerging phenomenon in patients with cancer. Abstract # 65. The 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. Granada, Spain June 27–30, 2004. International Journal of Infectious Diseases 2004; 8(Suppl1): S36. February 2, 2018/in Research Presentations/by Amar Safdar
